Latest News

  • All
  • Insights
  • Interviews
  • News
  • Newsletter
  • Reports
More

    Editor's Picks

    • All
    • Insights
    • Interviews
    • News
    • Newsletter
    • Reports
    More

      Reports

      • All
      • Insights
      • Interviews
      • News
      • Newsletter
      • Reports
      More
        Load More

        Must Read

        • All
        • Insights
        • Interviews
        • News
        • Newsletter
        • Reports
        More

          Quick Takeaways:  Why It Matters?  BiomEdit’s new patents effectively lock up its engineered Lactobacillus reuteri pvAb platform, giving it composition‑of‑matter and methods‑of‑use protection around BE‑101 and future in situ biologic payloads delivered via commensal bacteria.  BE‑101 is now positioned as a first‑of‑its‑kind, non‑antibiotic necrotic enteritis solution that could reach USDA CVB conditional licensure by Q3 2026 and commercial readiness by...